- $19.42m
- $17.51m
- $2.69m
Annual balance sheet for Neuraxis, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 1.9 | 0.321 | 0.254 | 0.079 | 3.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.311 | 0.115 | 0.174 | 0.073 | 0.245 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 2.46 | 0.491 | 0.477 | 0.243 | 4.27 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.302 | 0.246 | 0.189 | 0.159 | 0.375 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 2.79 | 0.76 | 1.48 | 0.509 | 4.76 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.01 | 1.42 | 6.98 | 1.89 | 2.43 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.15 | 1.59 | 7.05 | 1.91 | 2.69 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 1.64 | -0.826 | -5.57 | -1.4 | 2.07 |
Total Liabilities & Shareholders' Equity | 2.79 | 0.76 | 1.48 | 0.509 | 4.76 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |